




PHARMACEUTICAL 2017

Evofem Biosciences Inc.
Rank 130 of 292





PHARMACEUTICAL 2017

Evofem Biosciences Inc.
Rank 130 of 292

The relative strengths and weaknesses of Evofem Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evofem Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 106% points. The greatest weakness of Evofem Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 109%, being 106% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	12,507
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	902
Liabilities, Non-Current	0
Other Assets	200
Other Compr. Net Income	0
Other Expenses	1,036
Other Liabilities	0
Other Net Income	59
Other Revenues	0
Property and Equipment	109
Research and Development	6,579
Selling, General and Administrative Expense	5,464

Output Variable	Value in 1000 USD
Assets	12,817
Liabilities	902
Expenses	13,078
Revenues	0
Stockholders Equity	11,915
Net Income	-13,019
Comprehensive Net Income	-13,019
Economic Capital Ratio	109%